Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: Results of a phase I/IIa randomized, placebo-controlled, multicenter study

Y. Lévy; I. Sereti; G. Tambussi; J. P. Routy; J. D. Lelièvre; J. F. Delfraissy; J. M. Molina; M. Fischl; C. Goujard; B. Rodriguez; C. Rouzioux; V. Avettand-Fenoël; T. Croughs; S. Beq; M. Morre; J. F. Poulin; R. P. Sekaly; R. Thiebaut; M. M. Lederman

doi:10.1093/cid/cis383

Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: Results of a phase I/IIa randomized, placebo-controlled, multicenter study

Y. Lévy, I. Sereti, G. Tambussi, J. P. Routy, J. D. Lelièvre, J. F. Delfraissy, J. M. Molina, M. Fischl, C. Goujard, B. Rodriguez, C. Rouzioux, V. Avettand-Fenoël, T. Croughs, S. Beq, M. Morre, J. F. Poulin, R. P. Sekaly, R. Thiebaut, M. M. Lederman

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article

Abstract

Background. The immune deficiency of human immunodeficiency virus (HIV) infection is not fully corrected with ARV therapy. Interleukin-7 (IL-7) can boost CD4 T-cell counts, but optimal dosing and mechanisms of cellular increases need to be defined. Methods. We performed a randomized placebo-controlled dose escalation (10, 20 and 30 g/kg) trial of 3 weekly doses of recombinant human IL-7 (rhIL-7) in ARV-treated HIV-infected persons with CD4 T-cell counts between 101 and 400 cells/L and plasma HIV levels

Original language	English
Pages (from-to)	291-300
Number of pages	10
Journal	Clinical Infectious Diseases
Volume	55
Issue number	2
DOIs	https://doi.org/10.1093/cid/cis383
Publication status	Published - Jul 15 2012

Fingerprint

ASJC Scopus subject areas

Infectious Diseases
Microbiology (medical)

Cite this

Lévy, Y., Sereti, I., Tambussi, G., Routy, J. P., Lelièvre, J. D., Delfraissy, J. F., Molina, J. M., Fischl, M., Goujard, C., Rodriguez, B., Rouzioux, C., Avettand-Fenoël, V., Croughs, T., Beq, S., Morre, M., Poulin, J. F., Sekaly, R. P., Thiebaut, R., & Lederman, M. M. (2012). Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: Results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clinical Infectious Diseases, 55(2), 291-300. https://doi.org/10.1093/cid/cis383

Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy : Results of a phase I/IIa randomized, placebo-controlled, multicenter study. / Lévy, Y.; Sereti, I.; Tambussi, G.; Routy, J. P.; Lelièvre, J. D.; Delfraissy, J. F.; Molina, J. M.; Fischl, M.; Goujard, C.; Rodriguez, B.; Rouzioux, C.; Avettand-Fenoël, V.; Croughs, T.; Beq, S.; Morre, M.; Poulin, J. F.; Sekaly, R. P.; Thiebaut, R.; Lederman, M. M.

In: Clinical Infectious Diseases, Vol. 55, No. 2, 15.07.2012, p. 291-300.

Research output: Contribution to journal › Article

Lévy, Y, Sereti, I, Tambussi, G, Routy, JP, Lelièvre, JD, Delfraissy, JF, Molina, JM, Fischl, M, Goujard, C, Rodriguez, B, Rouzioux, C, Avettand-Fenoël, V, Croughs, T, Beq, S, Morre, M, Poulin, JF, Sekaly, RP, Thiebaut, R & Lederman, MM 2012, 'Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: Results of a phase I/IIa randomized, placebo-controlled, multicenter study', Clinical Infectious Diseases, vol. 55, no. 2, pp. 291-300. https://doi.org/10.1093/cid/cis383

Lévy Y, Sereti I, Tambussi G, Routy JP, Lelièvre JD, Delfraissy JF et al. Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: Results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clinical Infectious Diseases. 2012 Jul 15;55(2):291-300. https://doi.org/10.1093/cid/cis383

Lévy, Y. ; Sereti, I. ; Tambussi, G. ; Routy, J. P. ; Lelièvre, J. D. ; Delfraissy, J. F. ; Molina, J. M. ; Fischl, M. ; Goujard, C. ; Rodriguez, B. ; Rouzioux, C. ; Avettand-Fenoël, V. ; Croughs, T. ; Beq, S. ; Morre, M. ; Poulin, J. F. ; Sekaly, R. P. ; Thiebaut, R. ; Lederman, M. M. / Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy : Results of a phase I/IIa randomized, placebo-controlled, multicenter study. In: Clinical Infectious Diseases. 2012 ; Vol. 55, No. 2. pp. 291-300.

@article{7dcf4b081e8643fca52025ff5810120b,

title = "Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: Results of a phase I/IIa randomized, placebo-controlled, multicenter study",

abstract = "Background. The immune deficiency of human immunodeficiency virus (HIV) infection is not fully corrected with ARV therapy. Interleukin-7 (IL-7) can boost CD4 T-cell counts, but optimal dosing and mechanisms of cellular increases need to be defined. Methods. We performed a randomized placebo-controlled dose escalation (10, 20 and 30 g/kg) trial of 3 weekly doses of recombinant human IL-7 (rhIL-7) in ARV-treated HIV-infected persons with CD4 T-cell counts between 101 and 400 cells/L and plasma HIV levels ",

author = "Y. L{\'e}vy and I. Sereti and G. Tambussi and Routy, {J. P.} and Leli{\`e}vre, {J. D.} and Delfraissy, {J. F.} and Molina, {J. M.} and M. Fischl and C. Goujard and B. Rodriguez and C. Rouzioux and V. Avettand-Feno{\"e}l and T. Croughs and S. Beq and M. Morre and Poulin, {J. F.} and Sekaly, {R. P.} and R. Thiebaut and Lederman, {M. M.}",

year = "2012",

month = jul

day = "15",

doi = "10.1093/cid/cis383",

language = "English",

volume = "55",

pages = "291--300",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "NLM (Medline)",

number = "2",

}

TY - JOUR

T1 - Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy

T2 - Results of a phase I/IIa randomized, placebo-controlled, multicenter study

AU - Lévy, Y.

AU - Sereti, I.

AU - Tambussi, G.

AU - Routy, J. P.

AU - Lelièvre, J. D.

AU - Delfraissy, J. F.

AU - Molina, J. M.

AU - Fischl, M.

AU - Goujard, C.

AU - Rodriguez, B.

AU - Rouzioux, C.

AU - Avettand-Fenoël, V.

AU - Croughs, T.

AU - Beq, S.

AU - Morre, M.

AU - Poulin, J. F.

AU - Sekaly, R. P.

AU - Thiebaut, R.

AU - Lederman, M. M.

PY - 2012/7/15

Y1 - 2012/7/15

N2 - Background. The immune deficiency of human immunodeficiency virus (HIV) infection is not fully corrected with ARV therapy. Interleukin-7 (IL-7) can boost CD4 T-cell counts, but optimal dosing and mechanisms of cellular increases need to be defined. Methods. We performed a randomized placebo-controlled dose escalation (10, 20 and 30 g/kg) trial of 3 weekly doses of recombinant human IL-7 (rhIL-7) in ARV-treated HIV-infected persons with CD4 T-cell counts between 101 and 400 cells/L and plasma HIV levels

AB - Background. The immune deficiency of human immunodeficiency virus (HIV) infection is not fully corrected with ARV therapy. Interleukin-7 (IL-7) can boost CD4 T-cell counts, but optimal dosing and mechanisms of cellular increases need to be defined. Methods. We performed a randomized placebo-controlled dose escalation (10, 20 and 30 g/kg) trial of 3 weekly doses of recombinant human IL-7 (rhIL-7) in ARV-treated HIV-infected persons with CD4 T-cell counts between 101 and 400 cells/L and plasma HIV levels

UR - http://www.scopus.com/inward/record.url?scp=84864125153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864125153&partnerID=8YFLogxK

U2 - 10.1093/cid/cis383

DO - 10.1093/cid/cis383

M3 - Article

C2 - 22550117

AN - SCOPUS:84864125153

VL - 55

SP - 291

EP - 300

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 2

ER -

Access to Document

10.1093/cid/cis383